The Galactosemia Podcast podcast

Why BridgeBio Stopped Galactosemia Gene Therapy

0:00
18:34
Rewind 15 seconds
Fast Forward 15 seconds

BridgeBio recently stopped their research and development of gene therapy for Galactosemia. This came as a shock to many of us. I talked to the CEO of BridgeBio on the phone, and in this episode I report back what he told me. 

More episodes from "The Galactosemia Podcast"